Bio-Rad buys neonate screening test company:
This article was originally published in Clinica
Bio-Rad Laboratories is buying Perth, Scotland-based Quantase, which develops screening tests for neonates, a market estimated at more than $100 million worldwide, with a 10% growth rate. The deal, for an undisclosed amount, strengthens Hercules, California-based Bio-Rad's position in the genetic screening market. The company notes that genetic screening of newborns is compulsory in the US.